SEARCH:   Advanced

Blood, 15 April 2007, Vol. 109, No. 8, pp. 3489-3495. Prepublished online as a Blood First Edition Paper on January 5, 2007; DOI 10.1182/blood-2006-08-040410. This Article Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2006-08-040410v1 109/8/3489    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Avet-Loiseau, H. Articles by Mathiot, C. Search for Related Content PubMed PubMed Citation Articles by Avet-Loiseau, H. Articles by Mathiot, C. Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted August 15, 2006 Accepted September 21, 2006 Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome Herve Avet-Loiseau*, Michel Attal, Philippe Moreau, Catherine Charbonnel, Frederic Garban, Cyrille Hulin, Serge Leyvraz, Mauricette Michallet, Ibrahim Yakoub-Agha, Laurent Garderet, Gerald Marit, Lucienne Michaux, Laurent Voillat, Marc Renaud, Bernard Grosbois, Gaelle Guillerm, Lotfi Benboubker, Mathieu Monconduit, Catherine Thieblemont, Philippe Casassus, Denis Caillot, Anne-Marie Stoppa, Jean-Jacques Sotto, Marc Wetterwald, Charles Dumontet, Jean-Gabriel Fuzibet, Isabelle Azais, Veronique Dorvaux, Marc Zandecki, Regis Bataille, Stephane Minvielle, Jean-Luc Harousseau, Thierry Facon, and Claire Mathiot INSERM, U601, Nantes, France University, Hospital, Hematology Department, Toulouse, France Universite de Nantes, Hospital, Hematology Department, Nantes, France Universit de Nantes, Hospital, Hematology Laboratory, Nantes, France University, Hospital, Hematology Department, Grenoble, France University, Hospital, Hematology Department, Nancy, France University, Hospital, Hematology Department, Lausanne, Switzerland, for the SAKK University, Hospital, Hematology Department, Lyon, France University, Hospital, Hematology Department, Lille, France University, Hospital, Hematology Department, Paris, France University, Hospital, Hematology Department, Bordeaux, France University, Hospital, Hematology Department, Haine, Belgium University, Hospital, Hematology Department, Besancon, France University, Hospital, Hematology Department, Poitiers, France University, Hospital, Internal Medicine Department, Rennes, France University, Hospital, Hematology Department, Brest, France University, Hospital, Hematology Department, Tours, France Becquerel Cancer Center, Hematology Department, Rouen, France University, Hospital, Hematology Department, Pierre-Benite, France University, Hospital, Hematology Department, Bobigny, France University, Hospital, Hematology Department, Dijon, France Paoli Calmette Cancer Center, Hematology Department, Marseille, France Hospital, Hematology Department, Dunkerque, France University, Hospital, Internal Medicine Department, Nice, France University, Hospital, Rheumatology Department, Poitiers, France Hospital, Hematology Department, Metz, France University, Hospital, Hematology Laboratory, Angers, France Curie Cancer Center, Hematology Department, Paris, France * Corresponding author; email: herve.avetloiseau{at}chu-nantes.fr. Acquired genomic aberrations have been shown to significantly impact survival in several hematological malignancies. We analyzed the prognostic value of the most frequent chromosomal changes in a large series of patients with newly diagnosed symptomatic myeloma prospectively enrolled in homogeneous therapeutic trials. All the 1064 patients enrolled in the IFM99 trials conducted by the Intergroupe Francophone du Myelome benefited from an interphase fluorescence in situ hybridization analysis performed on purified bone marrow plasma cells. They were systematically screened for the following genomic aberrations: del(13), t(11;14), t(4;14), hyperdiploidy, MYC translocations, and del(17p). Chromosomal changes were observed in 90% of the patients. The del(13), t(11;14), t(4;14), hyperdiploidy, MYC translocations, and del(17p) were present in 48%, 21%, 14%, 39%, 13%, and 11% of the patients, respectively. After a median follow-up of 41 months, univariate statistical analyses revealed that del(13), t(4;14), non-hyperdiploidy, and del(17p) negatively impacted both the event free survival and the overall survival, whereas t(11;14) and MYC translocations did not influence the prognosis. Multivariate analyses on 513 patients annotated for all the parameters showed that only t(4;14) and del(17p) retained prognostic value for both the event free and overall survivals. When compared with the currently used International Staging System, this prognostic model compares favorably. In myeloma, the genomic aberrations t(4;14) and del(17p), together with 2-microglobulin level, are important independent predictors of survival. These findings have implications for the design of risk-adapted treatment strategies. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Multiple myeloma and FISH (but no CHIPS) Rafael Fonseca Blood 2007 109: 3132-3133. [Full Text] [PDF] This article has been cited by other articles: J.-L. Harousseau, H. Avet-Loiseau, M. Attal, C. Charbonnel, F. Garban, C. Hulin, M. Michallet, T. Facon, L. Garderet, G. Marit, et al. Achievement of at Least Very Good Partial Response Is a Simple and Robust Prognostic Factor in Patients With Multiple Myeloma Treated With High-Dose Therapy: Long-Term Analysis of the IFM 99-02 and 99-04 Trials J. Clin. Oncol., December 1, 2009; 27(34): 5720 - 5726. [Abstract] [Full Text] [PDF] S. K. Kumar, J. R. Mikhael, F. K. Buadi, D. Dingli, A. Dispenzieri, R. Fonseca, M. A. Gertz, P. R. Greipp, S. R. Hayman, R. A. Kyle, et al. Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines Mayo Clin. Proc., December 1, 2009; 84(12): 1095 - 1110. [Abstract] [Full Text] [PDF] J.-L. Harousseau, M. Attal, and H. Avet-Loiseau The role of complete response in multiple myeloma Blood, October 8, 2009; 114(15): 3139 - 3146. [Abstract] [Full Text] [PDF] H. Avet-Loiseau, C. Li, F. Magrangeas, W. Gouraud, C. Charbonnel, J.-L. Harousseau, M. Attal, G. Marit, C. Mathiot, T. Facon, et al. Prognostic Significance of Copy-Number Alterations in Multiple Myeloma J. Clin. Oncol., September 20, 2009; 27(27): 4585 - 4590. [Abstract] [Full Text] [PDF] V. J. Louw, H. Louw, M. J. Webb, J.-L. Harousseau, and P. Moreau Autologous Stem-Cell Transplantation for Multiple Myeloma N. Engl. J. Med., September 10, 2009; 361(11): 1118 - 1119. [Full Text] [PDF] D. Reece, K. W. Song, T. Fu, B. Roland, H. Chang, D. E. Horsman, A. Mansoor, C. Chen, E. Masih-Khan, Y. Trieu, et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13 Blood, July 16, 2009; 114(3): 522 - 525. [Abstract] [Full Text] [PDF] P. Kapoor, S. Kumar, R. Fonseca, M. Q. Lacy, T. E. Witzig, S. R. Hayman, A. Dispenzieri, F. Buadi, P. L. Bergsagel, M. A. Gertz, et al. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone Blood, July 16, 2009; 114(3): 518 - 521. [Abstract] [Full Text] [PDF] D. Hose, J. Moreaux, T. Meissner, A. Seckinger, H. Goldschmidt, A. Benner, K. Mahtouk, J. Hillengass, T. Reme, J. De Vos, et al. Induction of angiogenesis by normal and malignant plasma cells Blood, July 2, 2009; 114(1): 128 - 143. [Abstract] [Full Text] [PDF] L. Chiecchio, G. P. Dagrada, R. K.M. Protheroe, D. M. Stockley, A. G. Smith, K. H. Orchard, N. C.P. Cross, C. J. Harrison, F. M. Ross, and on behalf of the UK Myeloma Forum Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case Haematologica, July 1, 2009; 94(7): 1024 - 1028. [Abstract] [Full Text] [PDF] J.-L. Harousseau and P. Moreau Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma N. Engl. J. Med., June 18, 2009; 360(25): 2645 - 2654. [Full Text] [PDF] A. C. Sprynski, D. Hose, L. Caillot, T. Reme, J. D. Shaughnessy Jr, B. Barlogie, A. Seckinger, J. Moreaux, M. Hundemer, M. Jourdan, et al. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor Blood, May 7, 2009; 113(19): 4614 - 4626. [Abstract] [Full Text] [PDF] A. K. Stewart Reduced-intensity allogeneic transplantation for myeloma: reality bites Blood, April 2, 2009; 113(14): 3135 - 3136. [Full Text] [PDF] B. Bruno, M. Rotta, F. Patriarca, D. Mattei, B. Allione, F. Carnevale-Schianca, R. Sorasio, A. Rambaldi, M. Casini, M. Parma, et al. Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo Blood, April 2, 2009; 113(14): 3375 - 3382. [Abstract] [Full Text] [PDF] A. H. Bryce, R. P. Ketterling, M. A. Gertz, M. Lacy, R. A. Knudson, S. Zeldenrust, S. Kumar, S. Hayman, F. Buadi, R. A. Kyle, et al. Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis Haematologica, March 1, 2009; 94(3): 380 - 386. [Abstract] [Full Text] [PDF] A. A Saad, M. Sharma, and G. M Higa Treatment of Multiple Myeloma in the Targeted Therapy Era Ann. Pharmacother., February 1, 2009; 43(2): 329 - 338. [Abstract] [Full Text] [PDF] G. Desplanques, N. Giuliani, R. Delsignore, V. Rizzoli, R. Bataille, and S. Barille-Nion Impact of XIAP protein levels on the survival of myeloma cells Haematologica, January 1, 2009; 94(1): 87 - 93. [Abstract] [Full Text] [PDF] D. Reece, J.-L. Harousseau, and M. A. Gertz Nontransplant Therapy of Myeloma, High-dose Therapy for Myeloma, and a Personalized Care Plan for Treatment of Myeloma ASCO Educational Book, January 1, 2009; 2009(1): 502 - 509. [Abstract] [Full Text] [PDF] A. Dispenzieri Biology, treatment, and time Blood, October 15, 2008; 112(8): 2999 - 3000. [Full Text] [PDF] O. Decaux, L. Lode, F. Magrangeas, C. Charbonnel, W. Gouraud, P. Jezequel, M. Attal, J.-L. Harousseau, P. Moreau, R. Bataille, et al. Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du Myelome J. Clin. Oncol., October 10, 2008; 26(29): 4798 - 4805. [Abstract] [Full Text] [PDF] J Yeung and H Chang Genomic aberrations and immunohistochemical markers as prognostic indicators in multiple myeloma J. Clin. Pathol., July 1, 2008; 61(7): 832 - 836. [Abstract] [Full Text] [PDF] J. San-Miguel, J.-L. Harousseau, D. Joshua, and K. C. Anderson Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents J. Clin. Oncol., June 1, 2008; 26(16): 2761 - 2766. [Abstract] [Full Text] [PDF] T. Bochtler, U. Hegenbart, F. W. Cremer, C. Heiss, A. Benner, D. Hose, M. Moos, J. Bila, C. R. Bartram, A. D. Ho, et al. Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability Blood, May 1, 2008; 111(9): 4700 - 4705. [Abstract] [Full Text] [PDF] N. C. Munshi Investigative Tools for Diagnosis and Management Hematology, January 1, 2008; 2008(1): 298 - 305. [Abstract] [Full Text] [PDF] J.-P. Fermand Initial Therapy for Multiple Myeloma: Role of Stem Cell Transplantation ASCO Educational Book, January 1, 2008; 2008(1): 375 - 379. [Abstract] [Full Text] [PDF] A. K. Stewart A Risk-adapted Approach to Myeloma Therapy ASCO Educational Book, January 1, 2008; 2008(1): 380 - 384. [Abstract] [Full Text] [PDF] K. Mahtouk, D. Hose, J. De Vos, J. Moreaux, M. Jourdan, J. F. Rossi, T. Reme, H. Goldschmidt, and B. Klein Input of DNA Microarrays to Identify Novel Mechanisms in Multiple Myeloma Biology and Therapeutic Applications Clin. Cancer Res., December 15, 2007; 13(24): 7289 - 7295. [Abstract] [Full Text] [PDF] M. W. Jenner, P. E. Leone, B. A. Walker, F. M. Ross, D. C. Johnson, D. Gonzalez, L. Chiecchio, E. Dachs Cabanas, G. Paolo Dagrada, M. Nightingale, et al. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma Blood, November 1, 2007; 110(9): 3291 - 3300. [Abstract] [Full Text] [PDF] D. Gonzalez, M. van der Burg, R. Garcia-Sanz, J. A. Fenton, A. W. Langerak, M. Gonzalez, J. J. M. van Dongen, J. F. San Miguel, and G. J. Morgan Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma Blood, November 1, 2007; 110(9): 3112 - 3121. [Abstract] [Full Text] [PDF] FISHing for Risk Profiles in Multiple Myeloma Journal Watch Oncology and Hematology, May 7, 2007; 2007(507): 2 - 2. [Full Text] R. Fonseca Strategies for Risk-Adapted Therapy in Myeloma Hematology, January 1, 2007; 2007(1): 304 - 310. [Abstract] [Full Text] [PDF] M. Attal, P. Moreau, H. Avet-Loiseau, and J.-L. Harousseau Stem Cell Transplantation in Multiple Myeloma Hematology, January 1, 2007; 2007(1): 311 - 316. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020